ICSI Treatment in India
Get ICSI Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
ICSI Treatment in UAE
ICSI Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Intracytoplasmic Sperm Injection (ICSI) is the gold-standard assisted reproductive technology for overcoming severe male infertility, including azoospermia, severe oligospermia, and sperm motility disorders, achieving clinical pregnancy rates of 40–60% per embryo transfer cycle in experienced hands. GAF Healthcare connects international patients with India's and the UAE's most accredited fertility centers — institutions equipped with time-lapse embryo monitoring, vitrification platforms, and PGT-A (Preimplantation Genetic Testing for Aneuploidies) — offering world-class outcomes at a fraction of Western costs. Whether you choose India's high-volume specialist hubs or the UAE's luxury-tier clinics in Dubai and Abu Dhabi, GAF Healthcare manages every step of your cross-border fertility journey with clinical precision and end-to-end logistical support.
Hospital Stay: 0–1 days (egg retrieval and embryo transfer are outpatient day procedures; no inpatient admission required in most cases) • Total Stay in Country (Fit-to-Fly): 2–4 weeks total in-country stay (covers ovarian stimulation monitoring, egg retrieval, embryo culture, and transfer, plus a minimum 5–7 day post-transfer observation period before international travel) • Success Rate: 40–60% clinical pregnancy rate per embryo transfer (age-dependent; highest in women under 35 using own oocytes)
What Is It?
Intracytoplasmic Sperm Injection (ICSI) is a micromanipulation-based in vitro fertilization technique in which a single morphologically selected spermatozoon is directly injected into the cytoplasm of a mature (MII-stage) oocyte using a fine-gauge glass micropipette under inverted microscope guidance. This bypasses all natural sperm-oocyte interaction barriers — including zona pellucida penetration, capacitation, and acrosome reaction — making it the definitive treatment when male factor infertility is the primary barrier to conception. Indications span the full spectrum of severe male infertility: non-obstructive azoospermia (NOA) requiring surgical sperm retrieval, severe oligozoospermia (sperm concentration <1 million/mL), asthenozoospermia (total motility <10%), teratozoospermia (normal forms <1% by Kruger strict morphology criteria), antisperm antibody presence, and prior conventional IVF fertilization failure.
The physiological rationale for ICSI is well-established. In severe oligospermia or NOA, the sperm retrieved via microsurgical epididymal sperm aspiration (MESA), percutaneous epididymal sperm aspiration (PESA), testicular sperm extraction (TESE), or micro-TESE may be present in numbers too limited for conventional IVF insemination and may lack the motility or acrosomal integrity required for natural zona binding. ICSI circumvents these barriers by mechanically delivering a single sperm — selected using high-magnification IMSI (Intracytoplasmic Morphologically Selected Sperm Injection) at ×6,300 magnification or newer AI-assisted sperm selection platforms — directly into the egg cytoplasm, achieving fertilization rates of 60–80% of injected mature oocytes in optimized laboratory conditions.
The current standard of care integrates ICSI with stimulation protocols using recombinant FSH (rFSH) and LH, GnRH antagonist or agonist down-regulation, and individualized dosing guided by antral follicle count (AFC) and serum anti-Müllerian hormone (AMH) levels. Fertilized embryos are cultured for 5–6 days to the blastocyst stage in time-lapse incubators (EmbryoScope+), graded by Gardner criteria, and selectively transferred. Supernumerary blastocysts are vitrified using Cryotech or Kitazato protocols for future frozen embryo transfers (FET). Where indicated, PGT-A via next-generation sequencing (NGS) is performed on trophectoderm biopsies prior to transfer to screen for chromosomal aneuploidies, significantly improving implantation rates in advanced maternal age or recurrent implantation failure cases.
Candidates
• ELIGIBLE CANDIDATES (Male Factor Indications):
• Severe oligozoospermia: sperm concentration <5 million/mL (WHO 2021 reference values)
• Azoospermia (obstructive or non-obstructive): requires concurrent PESA, TESE, or micro-TESE for sperm retrieval
• Severe asthenozoospermia: total progressive motility <10%
• Severe teratozoospermia: Kruger strict morphology normal forms <1% (e.g., globozoospermia, macrozoospermia)
• High-titre antisperm antibodies (>50% antibody binding on MAR test)
• Prior failed conventional IVF cycles with zero or poor fertilization
• Ejaculatory dysfunction requiring electroejaculation or surgical retrieval
• Genetic carrier status in male partner requiring PGT-M (Preimplantation Genetic Testing for Monogenic disorders) alongside ICSI
• ELIGIBLE CANDIDATES (Female/Couple Indications):
• Unexplained infertility with failed IUI cycles (≥3 failed cycles)
• Advanced maternal age (≥35 years) with diminished ovarian reserve (AMH <1.1 ng/mL, AFC <7)
• Recurrent implantation failure (≥2 failed blastocyst transfers) where ICSI + PGT-A is recommended
• Fertility preservation before gonadotoxic chemotherapy or radiotherapy (using ICSI on cryopreserved oocytes)
• Donor egg recipients (ICSI routinely used for fertilization of donor oocytes)
• REQUIRED DIAGNOSTIC WORKUP BEFORE ICSI:
• Male: Semen analysis (×2, by WHO 2021 criteria), SCSA/DNA fragmentation index (DFI; concern if >25%), hormonal panel (FSH, LH, testosterone, prolactin, TSH), karyotype (46,XY confirmation), Y-chromosome microdeletion panel (AZFa, AZFb, AZFc), CFTR gene mutation screening (for bilateral absence of vas deferens/CBAVD), scrotal Doppler ultrasound
• Female: Transvaginal ultrasound (antral follicle count), serum AMH, Day-2/3 FSH and estradiol, LH, thyroid function (TSH, fT4), prolactin, complete blood count, coagulation screen (PT/aPTT), infectious disease screening (HIV, HBsAg, HCV, VDRL, Rubella IgG), uterine cavity assessment (3D SIS/hysteroscopy), karyotype if indicated
• Couple: Blood group and Rh typing, genetic counseling if carrier screening positive
• CONTRAINDICATIONS:
• Untreated uterine pathology precluding implantation (large submucosal fibroids, obliterative Asherman's syndrome not amenable to hysteroscopic correction)
• Active pelvic or systemic infection
• Uncontrolled endocrine disorders (uncontrolled hypothyroidism, poorly controlled diabetes)
• Severe OHSS risk without planned freeze-all strategy (bilateral PCO morphology, AMH >5 ng/mL without antagonist protocol and trigger modification)
• Non-obstructive azoospermia with AZFa or AZFb complete deletion (no viable sperm retrievable; donor sperm the only option)
• Female malignancy currently under active systemic chemotherapy (unless fertility preservation pre-treatment)
• Legal restrictions: same-sex couples or single women should confirm local legal eligibility in India or UAE before proceeding
Procedure
ICSI treatment is a multi-phase protocol. Below are the principal methods and technologies employed at GAF Healthcare partner centers in India and the UAE:
1. OVARIAN STIMULATION PROTOCOLS:
• GnRH Antagonist Protocol (most common for ICSI): rFSH (Gonal-F, Puregon) or biosimilar rFSH + rLH (Pergoveris) from Day 2/3 of cycle; GnRH antagonist (Cetrotide/Orgalutran) added when lead follicle reaches 13–14 mm; trigger with hCG (Ovitrelle 250 mcg) or GnRH agonist (Lupron 0.2 mg) in OHSS-risk patients; egg retrieval 34–36 hours post-trigger. Preferred for its flexibility, reduced OHSS risk, and shorter duration (10–12 days).
• GnRH Agonist Long Protocol: Down-regulation with daily buserelin/leuprolide from luteal phase Day 21; stimulation begins Day 2 of withdrawal bleed; total cycle ~28 days. Preferred for poor responders or patients with endometriosis.
• Mild/Mini-IVF Protocol: Clomiphene citrate + low-dose gonadotropins; fewer eggs retrieved but lower cost and OHSS risk; suitable for DOR patients or those preferring minimal intervention.
• POSEIDON Classification Stratification: Patients are classified into POSEIDON Groups 1–4 (based on age, ovarian reserve, and prior response) to individualize stimulation dose and approach.
2. SPERM RETRIEVAL TECHNIQUES (for azoospermia):
• PESA (Percutaneous Epididymal Sperm Aspiration): Needle aspiration of epididymis under local anesthesia; for obstructive azoospermia.
• MESA (Microsurgical Epididymal Sperm Aspiration): Open microsurgical exploration under general/spinal anesthesia; higher yield and quality.
• Conventional TESE (Testicular Sperm Extraction): Multiple testicular biopsies under local/general anesthesia.
• Micro-TESE (Microsurgical Testicular Sperm Extraction): Gold standard for NOA; operating microscope at ×15–25 magnification identifies dilated seminiferous tubules with active spermatogenesis, maximizing sperm retrieval rate (40–60% success in NOA) while minimizing testicular tissue damage. Available at select partner centers in India and UAE.
3. SPERM SELECTION TECHNOLOGIES:
• Standard ICSI: Sperm selected at ×200–400 magnification by experienced embryologist using motility and gross morphology criteria.
• IMSI (Intracytoplasmic Morphologically Selected Sperm Injection): Ultra-high magnification (×6,300) to identify and exclude sperm with nuclear vacuoles and head defects not visible at standard magnification; associated with improved embryo quality in severe teratozoospermia.
• PICSI (Physiological ICSI): Hyaluronic acid (HA)-binding dish selects sperm with mature chromatin and lower DNA fragmentation, mimicking the zona pellucida binding process; recommended when DNA fragmentation index (DFI) >25%.
• AI-Assisted Sperm Selection (SpermSearch, FERTILE PLUS): Emerging deep-learning platforms that analyze thousands of sperm frames per second to identify optimal candidates; available at premium UAE centers.
• Magnetic-Activated Cell Sorting (MACS): Annexin V columns remove apoptotic (DNA-damaged) sperm prior to ICSI; used in recurrent implantation failure cases.
4. EMBRYO CULTURE & MONITORING:
• Time-Lapse Incubation (EmbryoScope+, Miri TL, GERI+): Continuous embryo monitoring with automated morphokinetic annotation without disturbing the culture environment; AI-based ranking algorithms (KIDScore, iDAScore) guide blastocyst selection.
• Extended Culture to Day 5/6 Blastocyst: Significantly higher implantation rates vs. Day 3 cleavage-stage transfer (50–55% vs. 30–35% per transfer).
• Assisted Hatching (Laser AH): Infrared laser creates precise zona breach to facilitate blastocyst hatching; used in recurrent implantation failure, thick zona, or post-vitrification transfers.
5. EMBRYO SELECTION & TRANSFER:
• PGT-A (Preimplantation Genetic Testing for Aneuploidies): Trophectoderm biopsy on Day 5/6; NGS-based 24-chromosome screening; euploid blastocyst transfer reduces miscarriage rate and improves live birth rate in AMA patients and RPL. PGT-M for monogenic diseases; PGT-SR for structural rearrangements.
• Single Embryo Transfer (SET): International best practice; reduces multiple pregnancy risk without compromising cumulative live birth rates in good-prognosis patients.
• Endometrial Receptivity Assessment (ERA — Endometrial Receptivity Analysis): Endometrial biopsy analyzed by RNA sequencing to identify personalized window of implantation (WOI); recommended in recurrent implantation failure.
• EMMA/ALICE (Endometrial Microbiome/Infectious Chronic Endometritis testing): NGS-based endometrial microbiome profiling to identify Lactobacillus-depleted endometrium or chronic endometritis (Gardnerella, Streptococcus, etc.) and treat before transfer.
6. LUTEAL PHASE SUPPORT:
• Vaginal micronized progesterone (Cyclogest 400 mg BD or Utrogestan 200 mg TDS) from day of retrieval; some protocols add dydrogesterone (Duphaston) or injectable progesterone in oil for poor absorbers.
• Adjuvant therapies in recurrent failure: Low-molecular-weight heparin (LMWH) for thrombophilia, low-dose aspirin, intralipid infusion or IVIG for immune implantation failure, Growth Hormone co-stimulation for poor responders.
Cost of ICSI Treatment: India vs. UAE
ICSI treatment costs vary significantly between India and the UAE, reflecting differences in operational costs, real estate, staffing, and market positioning — without compromising laboratory technology or clinical outcomes. India offers the same global-standard IVF laboratory platforms (EmbryoScope+, vitrification, PGT-A via NGS) at 40–60% of UAE pricing, making it the preferred choice for cost-sensitive patients. The UAE — particularly Dubai (JCI-accredited Emirates Hospital, Mediclinic, Fakih IVF) and Abu Dhabi (Burjeel, Cleveland Clinic Abu Dhabi) — commands a premium for its luxury facilities, multilingual concierge services, and proximity for patients from the Middle East, Africa, and Europe. Both destinations are medically equivalent for ICSI success rates. The figures below represent all-inclusive per-cycle costs for a single ICSI cycle with fresh embryo transfer, covering stimulation monitoring, egg retrieval, ICSI procedure, embryo culture to blastocyst, and one fresh transfer. PGT-A, micro-TESE, ERA, EMMA/ALICE, and cryo-storage are add-ons priced separately.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $2,500 – $5,500 | ~47% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $5,000 – $10,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — REMOTE PRE-CYCLE CONSULTATION (Weeks 1–2, from home country):
• Upload all diagnostic reports to GAF Healthcare's secure patient portal (semen analysis, AMH, AFC scan, prior cycle records)
• Teleconsultation with designated IVF specialist at partner center in India or UAE
• Personalized stimulation protocol prescribed; local monitoring arrangements confirmed in home country (baseline scan, Day-2 bloods)
• GAF Healthcare initiates medical visa (e-MV) application for India or UAE entry documentation; travel insurance and accommodation confirmed
• Gonadotropin medications ordered via partner pharmacy (can be couriered to home country or dispensed on arrival)
PHASE 2 — STIMULATION & MONITORING (Days 1–10, in home country or on arrival):
• Stimulation injections begin Day 2/3 of menstrual cycle
• Follicular monitoring ultrasounds every 2–3 days (can be done locally and images shared with partner clinic)
• Arrival in India or UAE recommended by Day 6–8 of stimulation for in-person monitoring
• Final trigger injection administered when ≥2 follicles reach ≥18 mm mean diameter; precise timing communicated by clinic
PHASE 3 — EGG RETRIEVAL (Day of Trigger +34–36 hours; Outpatient Day Procedure):
• Transvaginal oocyte retrieval under IV sedation (propofol-based, 15–20 minutes); ultrasound-guided aspiration of follicles
• Average 8–15 oocytes retrieved in normal responders; mature (MII) oocytes identified by embryologist
• Concurrent sperm sample provided by male partner (masturbation or surgical retrieval if azoospermia: PESA/TESE/micro-TESE on same day)
• Patient rests 2–4 hours in recovery; discharged same day with analgesics and antibiotics
• ICSI performed within 4–6 hours of retrieval; fertilization checked at 16–18 hours (2 pronuclei = normal fertilization)
PHASE 4 — EMBRYO CULTURE (Days 1–6 Post-Retrieval):
• Embryos cultured in time-lapse incubator to Day 5/6 blastocyst stage
• Morphokinetic assessment and AI ranking of blastocysts on Day 5/6
• PGT-A biopsy performed if indicated (results in 7–10 working days; cycle converted to freeze-all if PGT-A planned)
• Daily fertilization and embryo development updates sent to patient via GAF Healthcare coordinator
PHASE 5 — EMBRYO TRANSFER (Day 5/6 for fresh transfer; or FET in subsequent cycle):
• Mock transfer performed (if not done previously) to assess uterine depth and angle
• Endometrial preparation confirmed: triple-line endometrium ≥8 mm on ultrasound
• Embryo transfer: soft catheter (Wallace, Cook) loaded with 1 blastocyst (SET) under abdominal ultrasound guidance; painless, 10-minute procedure; no anesthesia required
• Patient rests 30–60 minutes; discharged with progesterone support and instructions
• Luteal phase medications continued; activity restrictions: avoid heavy exercise, swimming, sexual intercourse for 2 weeks
PHASE 6 — POST-TRANSFER PERIOD & FIT-TO-FLY ASSESSMENT (Days 7–14 Post-Transfer):
• Day 7: Serum progesterone and estradiol check
• Day 10–12: First serum beta-hCG quantitative test (>25 mIU/mL = positive)
• Day 14: Repeat beta-hCG (doubling time should be 48–72 hours for viable pregnancy)
• If beta-hCG positive and doubling, patient may travel home at Day 14 post-transfer with detailed written medication plan and referral letter to home-country OB/GYN
• Day 21 post-transfer (if positive): Transvaginal ultrasound for gestational sac and fetal heartbeat confirmation (can be done in home country with GAF-arranged telemedicine follow-up)
• Supernumerary vitrified blastocysts remain stored at partner center (annual cryo-storage fees apply); can be used for future FET cycles
PHASE 7 — REMOTE FOLLOW-UP (Week 6–12, from home country):
• GAF Healthcare coordinator maintains weekly WhatsApp/telemedicine check-ins
• Medication weaning plan for progesterone support (usually continued to 10–12 weeks of pregnancy)
• All reports and discharge summary provided in internationally readable format for home-country specialist
Risks & Considerations
ICSI is a safe and extensively validated procedure, but patients must receive complete counseling on the following procedure-specific risks and considerations before travel:
Ovarian Hyperstimulation Syndrome (OHSS): The most clinically significant complication of controlled ovarian stimulation. Mild OHSS (bloating, mild discomfort) occurs in up to 20–33% of cycles. Moderate-to-severe OHSS (ascites, hemoconcentration, thromboembolism risk, hospitalization) occurs in 1–5% of cycles, predominantly in women with PCOS phenotype, AMH >4 ng/mL, or prior OHSS history. GAF Healthcare partner centers mitigate this risk by using GnRH antagonist protocols, GnRH agonist trigger instead of hCG in high-risk patients, cabergoline prophylaxis, and freeze-all strategies with delayed FET. Patients with moderate-to-severe OHSS must not fly until symptoms resolve (typically 7–14 days), potentially extending in-country stay.
Top Hospitals for ICSI Treatment
Frequently Asked Questions — ICSI Treatment
A complete ICSI cycle — including controlled ovarian stimulation monitoring, transvaginal egg retrieval, ICSI microinjection procedure, blastocyst-stage embryo culture in a time-lapse incubator, and one fresh embryo transfer — costs approximately $2,500 to $5,500 USD in India (at JCI- and NABH-accredited centers in cities such as Mumbai, Delhi, Chennai, and Hyderabad). The same procedure at JCI- and DHA-accredited centers in Dubai or Abu Dhabi typically ranges from $5,000 to $10,000 USD. India is therefore 40–60% more affordable for equivalent laboratory technology and clinical expertise. Add-on procedures such as PGT-A (Preimplantation Genetic Testing for Aneuploidies) add $1,500–$3,000 USD; micro-TESE for azoospermia adds $1,000–$2,500 USD; ERA (Endometrial Receptivity Analysis) adds $600–$1,200 USD; and blastocyst vitrification and cryo-storage are charged separately at both destinations. GAF Healthcare provides a fully itemized cost estimate in writing before any travel commitment, with no hidden fees.
International patients undergoing a fresh ICSI cycle should plan for a total in-country stay of 2 to 4 weeks. The timeline breaks down as follows: you may begin stimulation injections in your home country and arrive at the partner center around Day 6–8 of stimulation (approximately 1 week before egg retrieval), or arrive from Day 1 for full monitoring. Egg retrieval occurs on approximately Day 10–12 of stimulation. Embryo culture to the blastocyst stage takes 5–6 days. A fresh embryo transfer is performed on Day 5/6 after retrieval. Following transfer, a minimum rest period of 5–7 days is recommended before flying, allowing for the first beta-hCG blood test on Day 10–12 post-transfer. Most physicians advise against long-haul international flights (>4 hours) for at least 10–14 days post-transfer to avoid dehydration, venous thromboembolism risk, and physical stress during the critical early implantation window. Patients at high risk of Ovarian Hyperstimulation Syndrome (OHSS) — typically those with PCOS, high AMH, or a large number of eggs retrieved — may need to stay an additional 7–14 days until symptoms fully resolve, as OHSS is a contraindication to air travel. Frozen embryo transfer (FET) cycles, where all embryos are vitrified and transfer is deferred to a subsequent cycle, require only a 5–7 day in-country stay for the transfer portion. GAF Healthcare builds flexible accommodation and flight bookings for all patients to accommodate these contingencies.
The clinical pregnancy rate (confirmed intrauterine pregnancy on ultrasound) for ICSI at GAF Healthcare partner centers ranges from 40% to 60% per embryo transfer cycle, comparable to the best global IVF programs. Live birth rates — the most meaningful metric — are approximately 35–50% per transfer in women under 35 using their own eggs. These figures decline with advancing maternal age: approximately 30–40% in women aged 35–37, 20–30% in ages 38–40, and 10–15% in women over 40 using own oocytes. For patients using donor eggs (younger, chromosomally tested donors), live birth rates exceed 55–65% per transfer regardless of recipient age. Key factors that improve success rates at partner centers include: (1) Extended culture to the blastocyst stage (Day 5/6) rather than Day 3 cleavage stage — blastocyst transfer increases implantation rates by 15–20%. (2) Time-lapse incubation (EmbryoScope+) with AI-based embryo ranking (KIDScore, iDAScore). (3) PGT-A for euploid blastocyst selection — in women ≥38 or with recurrent implantation failure, transferring a confirmed euploid embryo raises per-transfer live birth rates to 50–65% and reduces miscarriage to <5%. (4) IMSI or PICSI for severe teratozoospermia or elevated sperm DNA fragmentation. (5) ERA testing to identify the personalized window of implantation in recurrent implantation failure cases. Cumulative live birth rates — accounting for all fresh and frozen transfers from one egg retrieval — reach 70–80% over 2–3 cycles in good-prognosis patients under 38. GAF Healthcare's partner centers provide individualized prognosis estimates based on your specific ovarian reserve markers (AMH, AFC), age, sperm parameters, and prior cycle history during your pre-cycle teleconsultation.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical travel coordination for ICSI patients traveling to India or the UAE, ensuring a seamless, stress-free experience:
VISA & DOCUMENTATION — INDIA:
• GAF Healthcare's documentation team assists with the e-Medical Visa (e-MV) application on India's official MHA portal. The e-MV is specifically designed for international medical tourists and is typically approved within 72 hours. It allows triple-entry with a stay of up to 60 days per visit, covering the full ICSI cycle and follow-up. An e-Medical Attendant Visa (e-MAV) is simultaneously processed for the partner or caregiver accompanying the patient.
• Required documents: appointment letter from partner hospital, passport copy, passport-size photo, bank statement, and travel itinerary — all coordinated by GAF Healthcare.
VISA & DOCUMENTATION — UAE (DUBAI / ABU DHABI):
• Citizens of 90+ countries receive visa-on-arrival or are visa-exempt for the UAE (14–30 days), covering a full ICSI cycle comfortably. For patients requiring a formal UAE entry visa, GAF Healthcare liaises with the partner hospital to issue a medical referral letter, which facilitates a 30-day medical visit visa through UAE immigration.
• DHA (Dubai Health Authority) and DOH (Abu Dhabi Department of Health) regulated partner clinics provide standardized consent and documentation in English and Arabic.
AIRPORT TRANSFERS & IN-CITY LOGISTICS:
• Private, air-conditioned airport transfers arranged for arrival and departure in all destination cities (Mumbai, Delhi, Chennai, Hyderabad, Bangalore, Dubai, Abu Dhabi).
• Dedicated driver assigned for clinic visits throughout the ICSI cycle (daily monitoring scans require 8–12 clinic visits over the total stay).
ACCOMMODATION:
• Partner hotels and serviced apartments within 5–15 minutes of the fertility center are pre-vetted for medical tourist suitability (kitchen access for medication refrigeration, quiet environment, reliable WiFi for teleconsultation).
• Options range from budget-friendly guesthouses (from $30/night in India) to 4–5 star hotels (from $150/night in Dubai), curated to the patient's budget.
• Attendant accommodation is arranged in the same property; family rooms and connecting suites available.
DEDICATED CASE COORDINATOR:
• Every GAF Healthcare patient is assigned a single point-of-contact medical case coordinator who speaks the patient's language (English, Arabic, Russian, French, Swahili, Bengali — available on request).
• Coordinator manages appointment scheduling, prescription relay, laboratory report translation, and daily WhatsApp updates on embryo development.
FINANCIAL TRANSPARENCY:
• Itemized cost estimates provided in writing before travel commitment, with no hidden charges.
• Secure partial pre-payment options via international wire transfer or online payment gateway.
• GAF Healthcare's price-match guarantee ensures patients receive the best published rate at partner centers.
POST-CYCLE REMOTE FOLLOW-UP:
• Telemedicine follow-up consultations arranged with the treating IVF specialist at 2 weeks and 6 weeks post-transfer.
• All discharge summaries, embryo reports, and laboratory results provided in internationally accepted format for continuity of care with home-country obstetricians.